A missed T3 dose is one of the most commonly discussed topics in thyroid research communities. Whether someone is following a Wilson's WT3 protocol, using slow release T3 for temperature stabilization, or working through a titration phase, the question of what to do when a dose is late arises regularly. The research community has converged on a decision tree that most self-directed research subjects follow, and it is grounded in the pharmacokinetics of liothyronine rather than arbitrary convention.
This post documents that decision tree and the pharmacological reasoning behind it. The core principle is consistent across all variations of T3 research: never double up to compensate for a missed dose. Everything else is a judgment call based on timing.
Research Grade · Discreet Worldwide Shipping
Wilson's SR-T3 Combo Kit
Research framing: The protocols described here are documented for research and informational purposes. T3 compounds are not approved for self-administration outside supervised clinical settings in most jurisdictions. See our FAQ on legality for context on how research subjects in different regions approach this material.
The Half-Life Argument
Understanding what to do when a dose is missed requires understanding what liothyronine does in the body over time - specifically the distinction between serum half-life and tissue half-life.
Serum half-life of liothyronine (immediate-release): approximately 2.5 hours. This means that after taking a standard immediate-release T3 tablet, serum T3 concentrations peak within 1-2 hours and then decline, reaching half their peak level by roughly the 2.5-hour mark. By 6-8 hours post-dose, serum T3 from a single immediate-release dose has largely cleared.
Serum half-life with SR-T3: The sustained-release matrix changes this profile substantially. Rather than a single sharp peak followed by rapid decline, SR-T3 produces a more gradual rise over 4-6 hours, a modest plateau, and a slower decline. The effective release window of 6-8 hours means the serum half-life calculation is less useful as a standalone number - what matters is that serum T3 levels remain above trough for longer than with immediate-release formulations.
Tissue half-life: This is the piece most research subjects underweight. Thyroid hormone's intracellular effects - particularly at the level of nuclear thyroid hormone receptors - persist well beyond the point at which serum T3 has declined. The cellular effect half-life of T3 is estimated at 24-48 hours by some researchers, substantially longer than the 2.5-hour serum half-life. This is why a single missed dose rarely produces an immediate or dramatic symptom collapse in well-adapted research subjects. The cellular machinery is still running on thyroid hormone that was delivered hours or days earlier.
What this means for missed-dose decisions: The serum half-life drives the decision about whether to take a late dose, because it determines whether taking the dose now will cause problematic serum stacking with the next scheduled dose. The tissue half-life explains why a single missed dose usually does not require panic - the cellular effects are buffered. Both pieces of information together explain why the decision thresholds land where they do.
The Decision Tree
View missed-dose decision tree discussed in research forums
| Time since missed dose | Action | Rationale |
|---|---|---|
| Less than 4 hours late | Take the dose now | SR-T3 still within normal release window |
| 4-12 hours late, next dose >6 hours away | Take the dose now | Allows serum coverage between doses |
| 4-12 hours late, next dose <6 hours away | Skip; take next dose on schedule | Prevents serum stacking |
| More than 12 hours late | Skip; resume normal schedule at next dose | Past effective window; doubling up risks overdose |
| Multiple consecutive missed doses (>2 days) | Resume at lower dose; titrate back up over 5-7 days | HPT axis re-suppression takes time |
CRITICAL: never double up to compensate for a missed dose. Doubling produces a serum peak that approximates an overdose, which can trigger palpitations, anxiety, and (rarely) more serious cardiovascular events.
The decision tree above is widely cited across thyroid research forums and is consistent with the pharmacokinetic logic outlined in the half-life section. The thresholds are not arbitrary: the 4-hour mark corresponds roughly to the point at which a standard SR-T3 dose has delivered most of its sustained-release payload; the 12-hour mark corresponds to the outer boundary of any meaningful serum contribution from the missed dose.
Why Doubling Up Is Dangerous
The most common error research subjects make after a missed dose is attempting to compensate at the next dosing window by taking twice the normal amount. This is pharmacologically unsound and carries meaningful risk.
Consider a typical SR-T3 research subject taking 30 mcg per dose on a twice-daily schedule. A single dose produces a serum T3 profile with a peak in the range of normal physiological T3 levels. The cardiovascular and adrenergic systems adapt to this profile. Now consider what happens when that subject takes 60 mcg at the next dose.
With SR-T3, the sustained-release matrix moderates the spike to some degree - the release is still stretched over 4-8 hours rather than delivered as a bolus. But the total serum load is doubled. Peak serum T3 over the subsequent 6-8 hours will be approximately twice the normal range for that individual. The HPT (hypothalamic-pituitary-thyroid) axis suppression is dose-dependent; a doubled dose drives TSH suppression deeper and faster than the adapted state can accommodate without symptoms.
The cardiovascular effects of excess T3 are well-documented. Supraphysiological T3 stimulates cardiac beta-adrenergic receptors, increasing heart rate, contractility, and in some cases inducing arrhythmia. Research subjects on SR-T3 who have doubled up report palpitations as the most common symptom, often beginning 2-4 hours after the double dose and lasting 6-12 hours. Anxiety and tremor are also common. Severe cases - particularly in research subjects with underlying cardiac conditions - carry risk of more serious cardiovascular events.
For immediate-release T3 (Cytomel or liothyronine tablets), the risk is compounded further. The doubled dose produces a sharp serum spike rather than a moderated release, and the peak T3 exposure is both higher and faster-arriving than with SR-T3. The argument against doubling up applies to both formulations, but is especially critical for immediate-release.
The pharmacokinetic bottom line: a missed dose creates a temporary serum gap that is partially buffered by tissue half-life. Doubling up does not fill that gap retroactively - it creates a new peak that exceeds normal exposure. The gap is tolerable; the peak is not.
The Wilson's WT3 Protocol Missed-Dose Pattern
Research subjects following the Wilson's WT3 protocol face a specific complication with missed doses that does not apply equally to general T3 supplementation. The WT3 protocol is built around temperature stabilization - the goal is to reach and hold 98.6°F (37°C) oral temperature for at least three weeks. Missed doses disrupt this stabilization in a predictable pattern.
During the titration phase: A single missed dose during upward dose titration typically produces a temperature drop of 0.3-0.8°F within 12-24 hours, depending on where the research subject is in the titration curve. Most WT3 protocol guides indicate that this sets the titration back by 2-4 days - the subject often needs to hold at the current dose or step back one dose increment before resuming upward titration.
During the sustained-temperature phase: Once a research subject has reached target temperature and entered the three-week stability window, a single missed dose often produces a smaller temperature effect than during titration, because the body's baseline metabolism has been more substantially reset. However, multiple consecutive missed doses (more than two days of missing every dose) during this phase may require restarting the three-week countdown, as temperature stability has been interrupted.
The temperature log is the guide: WT3 protocol research subjects track oral temperatures multiple times daily. The temperature log provides the data to determine whether a missed dose has caused a meaningful disruption or whether the research subject has recovered within a day. A single temperature reading below target after a missed dose does not automatically require restarting the countdown - a pattern of readings below target over 48-72 hours is the more reliable signal.
For a detailed walkthrough of the WT3 protocol structure and how temperature targets interact with dose adjustments, see our guide to the Wilson's WT3 protocol.
The Pharmacokinetic Distinction for SR-T3
Of all the T3 formulations used by research subjects, slow release T3 is the most forgiving when it comes to missed doses. This is not an accident of formulation - it is a direct consequence of the extended release profile.
When a research subject on immediate-release Cytomel or liothyronine tablets misses a dose, the serum gap is sharp and relatively rapid. Serum T3 from the previous dose has likely cleared by the time the missed dose was due, and the next 4-6 hours (until the next scheduled dose) involve genuinely low T3 serum levels. Research subjects on immediate-release T3 frequently report noticing a missed dose within 6-8 hours - fatigue, mild cold intolerance, and cognitive sluggishness are common early signals.
SR-T3's sustained-release matrix changes this dynamic. Because the dose is released over 4-8 hours rather than absorbed within 30-60 minutes, the serum trough between doses is shallower than with immediate-release. A missed dose on an SR-T3 schedule produces a serum gap, but it is a more gradual decline from a shallower trough. The result: most research subjects on SR-T3 who miss a single dose report either no noticeable symptom or only mild and late-onset fatigue. The tissue half-life buffering described earlier has more time to act before serum levels drop to a point that produces symptomatic effects.
This pharmacokinetic advantage is one of the reasons research subjects often prefer SR-T3 over immediate-release Cytomel for long-term protocols - the margin of error on timing is larger, and the consequence of occasional schedule disruption is smaller. SR-T3 does not eliminate the missed-dose problem, but it reduces its clinical significance for most research subjects.
For a thorough comparison of SR-T3 versus immediate-release formulations and how their pharmacokinetic profiles differ in practice, see our complete guide to sustained-release T3. Research subjects interested in SR-T3 for this reason can review the Wilson's SR-T3 Combo Kit for formulation details.
What to Monitor After a Missed Dose
For most well-adapted research subjects on stable SR-T3 doses, a single missed dose produces nothing detectable. For research subjects earlier in their protocol or using immediate-release T3, some monitoring is useful.
Body temperature: For Wilson's WT3 protocol research subjects, oral temperature is the primary and most sensitive indicator. A drop of more than 0.5°F from the recent average, sustained across two or more readings, suggests the missed dose has produced a meaningful gap. Research subjects not on the WT3 protocol can still use temperature as a general indicator of thyroid status, though the signal is less precise outside the structured protocol context.
Fatigue: The most commonly reported early symptom of a missed T3 dose across formulations. Research subjects describe it as a qualitatively different fatigue from ordinary tiredness - heavier, less responsive to caffeine or rest, often accompanied by mild brain fog. This typically appears 8-16 hours after the missed dose on SR-T3 and 4-8 hours after on immediate-release.
Cold intolerance: A secondary signal, less sensitive than fatigue in most research subjects. Hands and feet are the usual first indicators.
Cognitive symptoms: Brain fog, word-finding difficulty, and reduced concentration are reported by some research subjects after missed doses, particularly those who use T3 for cognitive indications. These symptoms, when they appear, tend to lag fatigue by several hours.
What not to over-interpret: A single missed dose in a research subject who has been on a stable protocol for more than 4-6 weeks should produce, at most, mild and transient symptoms. If a single missed dose produces severe or rapid-onset symptoms, this is a signal to review the overall protocol with appropriate professional guidance rather than simply addressing the missed dose.
What Research Has and Hasn't Established
Established:
The serum half-life of liothyronine (T3) is approximately 2.5 hours for immediate-release formulations - this is consistent across multiple pharmacokinetic studies and is well-documented in the published literature. Tissue half-life of thyroid hormone exceeds serum half-life substantially; intracellular thyroid hormone effects persist for 24-48 hours or more after serum levels decline. Thyroid hormone overdose produces cardiovascular and adrenergic effects - increased heart rate, palpitations, potential arrhythmia - that are dose-dependent and clinically meaningful, particularly in individuals with underlying cardiac conditions.
Hypothesis:
The specific decision-tree thresholds used by research communities - the 4-hour and 12-hour cutoffs - are derived from half-life math and community convention rather than from controlled trials comparing outcomes at different thresholds. There is no published study that has head-to-head compared "take within 4 hours" versus "take within 6 hours" or other threshold variations. The thresholds are pharmacologically reasonable and widely cited, but they represent applied reasoning rather than directly validated experimental results.
Not endorsed by mainstream endocrinology:
The missed-dose framework described in this post extends general missed-medication principles into a research-community-specific protocol context. Mainstream endocrinology does not produce dosing guidelines for unsupervised T3 self-administration, and the WT3 protocol-specific guidance on temperature monitoring and countdown restarting is not part of standard clinical thyroidology. Research subjects using these frameworks should understand they are operating within community-developed conventions rather than formal clinical guidelines.
Frequently Asked Questions
What should I do if I miss a slow release T3 dose?
Check how late you are. If less than 4 hours late, take the dose now. If 4-12 hours late, check how far away your next scheduled dose is - if it is more than 6 hours away, take the missed dose now; if it is less than 6 hours away, skip the missed dose and take the next one on schedule. If more than 12 hours late, skip the missed dose entirely and resume your normal schedule at the next dose time.
Can I double my next dose to make up for a missed dose?
No. Doubling up is the one action the research community consistently identifies as the wrong response to a missed dose. A double dose produces a serum T3 peak approximately twice the normal range, which carries risk of palpitations, anxiety, tremor, and in susceptible individuals, more serious cardiovascular effects.
Why is doubling up dangerous?
Liothyronine acts on cardiac tissue through beta-adrenergic receptor stimulation. At normal doses, this effect is within physiological range. At double the normal dose, the cardiac stimulation can exceed that range, producing tachycardia (elevated heart rate), palpitations, and in some cases arrhythmia. The risk is higher with immediate-release T3 (sharp spike) than SR-T3 (moderated release), but exists with both.
How late is "too late" to take a missed dose?
The research-community convention is 12 hours. Beyond 12 hours from the scheduled dose time, the serum contribution of the missed dose is essentially nil, and the risk-benefit calculation no longer supports taking it. Taking a dose 12+ hours late does not meaningfully fill the serum gap that has already occurred; it only moves the dosing timeline forward in a way that increases the risk of stacking with the next scheduled dose.
What if I miss multiple SR-T3 doses in a row?
If more than two days of doses have been missed, resume at a lower dose than your established maintenance dose and titrate back up over 5-7 days. The reasoning is that the HPT axis, which has been suppressed by exogenous T3, begins to show early signs of re-activation after 48+ hours without T3 input. Returning directly to the full maintenance dose under these conditions risks overshooting.
Does Wilson's WT3 protocol restart if I miss doses?
It depends on the phase. A single missed dose during the titration phase typically delays reaching target temperature by 2-4 days but does not require a full restart. Multiple consecutive missed doses during the three-week stability phase may require restarting the three-week countdown, because temperature stability has been disrupted. The temperature log is the primary guide to this decision.
Are missed doses on SR-T3 different from missed doses on Cytomel?
Yes, meaningfully so. SR-T3's 4-8 hour release window produces a shallower serum trough between doses and a slower decline after a missed dose. Research subjects on SR-T3 typically have more time to recognize and respond to a missed dose before symptoms appear, compared to immediate-release Cytomel users, who often notice a missed dose within 4-8 hours as serum T3 clears more quickly.
Should I monitor anything after a missed dose?
For Wilson's WT3 protocol research subjects, continue temperature monitoring on the normal schedule and note whether temperature drops more than 0.5°F from recent average. For other research subjects, monitor for early fatigue and cold intolerance as primary indicators. Most single missed doses on SR-T3 produce no monitoring-detectable effect in well-adapted research subjects.
Closing Note
Missed doses are an ordinary part of any long-term research protocol - schedules change, sleep disrupts timing, and life does not always accommodate fixed dosing windows. The framework described here gives research subjects a pharmacologically grounded approach to these situations without resorting to compensatory double-dosing.
For the broader context of SR-T3 dosing decisions - including how to approach titration, symptom interpretation, and schedule adjustments - see our complete SR-T3 dosing troubleshooting guide. Research subjects looking for SR-T3 compounds can review the Wilson's SR-T3 Combo Kit and browse the full research compound catalog for related formulations.